Want to join the conversation?
$ENDP said it is making good progress with XIAFLEX which is leading to continued growth. In the Peyronie's disease market, the company delivered nearly 20% demand growth in 2Q16 versus 2Q15. Revenues in 2Q16 were impacted by higher destocking. $ENDP expects low double-digit pro forma revenue growth for full-year 2016.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.